Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496767 · ClinicalTrials.gov registry record · Phase 3
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
NCT02496767 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 744 participants.
The verdict
NCT02496767, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
Study Summary
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
Interventions
- DRUG Placebo tablets
- DRUG Tirasemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496767
The ClinicalTrials.gov registry entry for NCT02496767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablets is the first listed.
NCT02496767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02496767 about?
NCT02496767 is a clinical study titled "Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year". This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
What is the current status of trial NCT02496767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2015-09-03. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT02496767?
The interventions under investigation include: Placebo tablets (DRUG), Tirasemtiv (DRUG).
Who is sponsoring clinical trial NCT02496767?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.